7/ In most recent earnings, I check the headline numbers:
Revenue growth: 23% to $569 million
Revenue vs. Wall Street expectations (beat by 1.88%)✅
non-gaap EPS growth: -21% to $0.91
EPS vs. Wall Street expectations (meet expectation)✅
8/ Results vs. guidance
Management issued yearly guidance for 2020 in Q3 2020
Revenue +29% to $1.9 billion (actual +31% to $1.93 billion)✅
Non-GAAP Gross margin 66% (actual 66.7%)✅
Non-GAAP Operating margin 16% (actual 16.5%)✅
9/ Balance Sheet
$2.71 billion cash
$1.67 billion long-term convertible notes
10/
Margins
Use transcript / press release / or calculate yourself
Gross 70.2% vs. 66.8% (gross profit grew faster than revenue)
Non-gaap Operating: 18.3% vs. 22.5% (investigate!)
non-gaap Net: 15.8% vs. 22.9% (investigate!)
11/
News from press release?
✅Building out salesforce (explains operating margin & net margin drop)
✅Reimbursement in France
12/
Read through transcript:
✅Gross margin ⬆️ from new manufacturing facility
✅Super bowl commerical
✅New service center in Lithuania
✅New manufacturing site in Malaysia
✅New sensor launching in 2nd half 2021
✅Enter VC space
13/ Transcript
✅50% of sales now coming through pharmacy
✅International sales 35% of revenue
✅International DTC campaign launching
14/
2021 Guidance:
Revenue:
Management expects 15% to 20% growth
Wall Street expects 21%
Margins:
Gross ⬇️ to 65%
Operating ⬇️ 13%
15/
Management has a long history of under-promising & over-delivering, so I view these numbers as the floor, not the ceiling
16/
My big takeaways:
✅Revenue growing
✅Gross margin expanding
✅International expansion
✅Reinvestment year causing bottom-line to look worse
🛑2021 Margins will be weak
✅Move to pharmacy working
✅G7 launching in 2021
✅VC fund adds optionality
THESIS ON TRACK
17/
If you own $DXCM, the best move is to continue to do nothing
18/
Best guess is that $DXCM is in the top of the 5th inning of its growth cycle
19/ I email financial graphics like these every day for free